- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy
- Biological · Drug
- Lead sponsor
- Human Genome Sciences Inc., a GSK Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 503 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Covina, California • La Palma, California + 49 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1417–1440
of 6,861
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Interventions
- Standard of care liver biopsy, Fibroscan, Biospecimen Collection
- Procedure · Other
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Parkinson Disease
- Interventions
- sumanirole, ropinirole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 93
- States / cities
- Hot Springs, Arkansas • Little Rock, Arkansas • Carmichael, California + 81 more
- Conditions
- Asthma
- Interventions
- Fluticasone furoate 50mcg, Fluticasone propionate 100mcg, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Rolling Hills Estates, California • Sacramento, California + 17 more
- Conditions
- Melanoma
- Interventions
- Fianlimab, Cemiplimab, Pembrolizumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 28
- States / cities
- La Jolla, California • San Francisco, California • Santa Monica, California + 21 more
- Conditions
- Visual Acuity
- Interventions
- JJVC Investigational Multifocal Contact Lenses manufactured in senofilcon A C3
- Device
- Lead sponsor
- Johnson & Johnson Vision Care, Inc.
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 12
- States / cities
- Jacksonville, Florida • Maitland, Florida • Tallahassee, Florida + 8 more
- Conditions
- Depressive Disorder, Major
- Interventions
- LY2216684
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • San Antonio, Texas
- Conditions
- Amyotrophic Lateral Sclerosis, Renal Insufficiency
- Interventions
- Dexpramipexole (dose 1), Dexpramipexole (dose 2)
- Drug
- Lead sponsor
- Knopp Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Brooklyn Center, Minnesota
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- 100mg SPN-812, Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 48 Months to 69 Months
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 54
- States / cities
- Saraland, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 49 more
- Conditions
- Advanced Solid Tumors
- Interventions
- Talazoparib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 11
- States / cities
- Alhambra, California • Bakersfield, California • Fullerton, California + 7 more
- Conditions
- Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Reconstruction, Joint Instability
- Interventions
- Anterior cruciate ligament reconstruction (ACLR), Lateral extra-articular tenodesis (LET)
- Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 14 Years to 25 Years
- Enrollment
- 1,272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 14
- States / cities
- Redwood City, California • San Francisco, California • Orlando, Florida + 11 more
- Conditions
- Breast Cancer
- Interventions
- chemotherapy
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 624 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 296
- States / cities
- Anniston, Alabama • Anchorage, Alaska • Jonesboro, Arkansas + 210 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- temozolomide, DNA methylation analysis, laboratory biomarker analysis, adjuvant therapy, quality-of-life assessment, radiation therapy
- Drug · Genetic · Other + 2 more
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 751 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2029
- U.S. locations
- 72
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 57 more
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- Intense Education Intervention
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,049 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 41 more
- Conditions
- Head and Neck Cancer, Human Papilloma Virus
- Interventions
- MEDI0457, CELLECTRA®5P device, Durvalumab
- Drug · Device
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 14
- States / cities
- San Francisco, California • Orlando, Florida • Atlanta, Georgia + 10 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- PF-04236921
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 68
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Fair Oaks, California + 42 more
- Conditions
- Implantable Defibrillator User
- Interventions
- Not listed
- Lead sponsor
- Biotronik, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,694 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 68
- States / cities
- Gadsden, Alabama • Avondale, Arizona • Glendale, Arizona + 65 more
- Conditions
- Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
- Interventions
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Leucovorin, Levoleucovorin, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Prednisolone, Prednisone, Therapeutic Hydrocortisone, Thioguanine, Venetoclax, Vincristine
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 365 Days
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 116
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 100 more
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Linaclotide, Matching Placebo
- Drug
- Lead sponsor
- Ironwood Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 95
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 81 more
- Conditions
- Enterovirus, Rhinovirus
- Interventions
- Nitazoxanide, Placebo
- Drug
- Lead sponsor
- Romark Laboratories L.C.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,756 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Pelham, Alabama • Hot Springs, Arkansas + 36 more
- Conditions
- Renal Impairment
- Interventions
- AZD5004
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Miami Lakes, Florida • Orlando, Florida
- Conditions
- Cystic Fibrosis
- Interventions
- VX-659/TEZ/IVA, IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 484 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 44 more
- Conditions
- Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Placebo, Enicepatide
- Drug
- Lead sponsor
- Carmot Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Yuma, Arizona + 45 more
- Conditions
- Pediatric Cancer, Quality of Life
- Interventions
- SPARK Symptom Screening Linked to Feedback to Providers
- Behavioral
- Lead sponsor
- The Hospital for Sick Children
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 445 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Los Angeles, California • Redwood City, California + 17 more